Milestone Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Milestone Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $6.33. The average 1-year stock price forecast is 414.63% higher than the current stock price, while the lowest is $2.00 (+62.60%) and the highest is $8.00 (+550.41%).

Price Target: $6.33 (+414.63%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.00	$6.33	$7.00	$8.00
Change	+62.60%	+414.63%	+469.11%	+550.41%

Analyst Ratings

The average analyst rating for Milestone Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	4	4
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brandon Folkes H.C. Wainwright	H.C. Wainwright	Buy Maintains $8	Buy	Maintains	$8	+550.41%	May 26, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $7	Buy	Reiterates	$7	+469.11%	May 14, 2026
Ritu Baral TD Cowen	TD Cowen	Buy Maintains $8	Buy	Maintains	$8	+550.41%	May 13, 2026
Tiago Fauth Raymond James	Raymond James	Buy Initiates $6	Buy	Initiates	$6	+387.80%	Apr 9, 2026
Mohit Bansal Wells Fargo	Wells Fargo	Buy Maintains $4 → $8	Buy	Maintains	$4 → $8	+550.41%	Dec 16, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

7.14M

from 1.55M

362.08%

from 1.55M

Revenue Next Year

29.53M

from 7.14M

313.33%

from 7.14M

EPS This Year

-0.97

from -0.75

EPS Next Year

-1.05

from -0.97

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	15.00M	5.00M	1.00M	-	1.55M	7.14M
Revenue Growth	-	-66.67%	-80.00%	-	-	362.08%
Gross Profit	15.00M	5.00M	1.00M	-	1.55M	5.78M
Gross Margin	100.00%	100.00%	100.00%	-	100.00%	80.90%
Operating Income	-43.07M	-59.64M	-61.10M	-42.10M	-62.14M	-104.95M
Net Income	-42.85M	-58.39M	-59.69M	-41.52M	-63.06M	-112.43M
EPS	-	-	-	-	-0.75	-0.97
Free Cash Flow	-17.05M	-31.36M	-28.29M	-18.12M	-28.90M	-81.50M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	10.3M
Avg	7.1M
Low	4.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	566.2%
Avg	362.1%
Low	158.7%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.97
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-